姜黄素与STI571对慢性粒细胞白血病细胞株K562作用的体外研究

In Vitro Study of the Combination of Curcumin and STI571 on Chronic Myelogenous Leukemia Cell Line K562

目的研究姜黄素(Cur)、STI571以及二者联合应用对慢性粒细胞白血病细胞株K562的影响,探索两药的不同效果及联合应用机制。方法锥虫蓝排染法计算K562细胞增殖抑制率;Western blot方法检测Cur、STI571以及二者联合应用对K562细胞P210bcr/abl蛋白含量及其下游信号蛋白激酶C(PKC)的影响;用金氏公式评价两药的协同效果。结果Cur和STI571联合应用对K562细胞呈剂量依赖性的抑制作用,协同指数Q值均>0.85;Western blot显示,Cur和STI571联合应用对P210bcr/abl及PKC的下调呈明显增强作用。结论Cur与低剂量(0.1,0.15μmol/L)的STI571联合应用对抑制K562细胞增殖呈单独相加;而较大剂量则可明显协同下调P210bcr/abl和PKC的表达水平。

Objective To investigate the effects of the combination of curcumin（Cur） and STI571 on chronic myelogenous leukemia（CML） cell line K562. Methods Trypan blue exclusive staining was used to assess the inhibition of K562 cells; Western blot was used to assess the expression level of P210^bcr/abl protein and PKC after treatment with Cur, STI571 or their combination; Jin＇s formula was used to assess the synergistic effects between Cur and STI571. Results Combination of Cur and STI571 exerted dose-dependant effects on the inhibition of K562 cells, their combination indexes q〉0.85. Western blot showed that the combination of Cur and STI571 shows exerted synergistic down-regulation of P210^bcr/abl protein and PKC. Conclusion The combination of Cur and lower doses of STI571 simple synergistic inhibition of K562 cell growth; while a comparatively large doses of STI571 and Cur synergistically reduced significantly of P210^bcr/abl protein and PKC.